SUBJECT INDEX

A

ACE (See Angiotensin-converting enzyme)
Acetaminophen, 91–97
  cytochromes P450 and, 92–96
  hepatic necrosis induced by, 92–94
  hepatotoxicity
    glutathione protective against, 92
    mitochondrion and, 94–95
    protein adducts and, 93–97
Actylation polymorphism, 269–77
  association with drug toxicity, 271
  interethnic variability and evolution, 276–77
  molecular mechanism of, 271–76
    NAT2 genetic variability, 273–76
    NAT2 locus, 269–70, 272–76
Acetylcholinesterase, 84
N-Acetyltransferases, 269–70, 272–76
  NAT2 polymorphism, 269–70, 272–76
Acidic fibroblast growth factor, 241
Acupuncture, 23
Acute nervous system injury, 251–52
  neurotrophic therapy for, 251
Acyl CoA cholesterol acyl transferase (ACAT), 482
Adenosine deaminase, 84
S-Adenosylmethionine (SAM), 398–400
Adenyl cyclase
  $G_{\beta\gamma}$ subunit and, 185–86
Addiction
  as a brain disease, 26
  methadone treatment for, 14–20
Addiction Research Foundation, 16–18
Adipose tissue
  brown, 431–32, 438, 442–46
  white, 431–32, 438, 442–46
β_3-Adrenergic receptor, 421–47
  adenyl cyclase activation studies, 421
  adipose tissue and, 431–32, 438, 442–46
  amino acide homology with other species, 424–28
  antiobesity and antidiabetic drugs based on, 421, 431–32, 438–40
  cloning of gene and cDNA, 422–23
  comparison with β_1, β_2, 421–24
    number of residues conserved, 424
  distribution, 430–33
    human mRNA and, 432–33
  G_s protein interaction site, 429–30
  ligand-binding
    site, 428–29
    studies, 421
  ligands, 433–40
    structure, 433, 438
  pharmacology, 433–40
  polymorphism in humans, 428
  regulation of expression and functions, 440–42
  thermogenesis, 421
β-Adrenergic receptor system, 131–33, 421–47
Adrenergic receptors, 421–47
  β_1 and β_2, 421–22, 424, 430–31, 439–41
  (See also β_3-Adrenergic receptor)
Adult respiratory distress syndrome (ARDS), 330
  Affymax, 19–20
Ah receptor, 309
Airway reactivity
  cigarette sidestream smoke and, 29–30, 45–47
Alcoholic liver disease, 103–4, 106, 327, 333, 335
  heme oxygenase-1 and, 529
Alzheimer's disease
  NGF therapy for, 250–51
δ-Aminolevulvinate synthase (ALAS), 518, 535
Amodiaquine
  hepatotoxicity and, 98, 106
    protein adduct, 106
Amyotrophic lateral sclerosis (ALS), 241, 244–47
  ciliary neurotrophic factor for treatment of, 241, 245–46
  insulin-like growth factor for treatment of, 246
Angiotensin
  in blood vessels or vascular bed, 58–61
Angiotensin-converting enzyme (ACE), 53–66, 131
  deficient mice, 131
  inhibitors
    capropril, 56, 62–63
    enalapril, 63, 65
    kinnase-2 inhibitory properties of, 56
    lisinopril, 61–62
    losartan, 61–63
    ramipril, 65
    renal hemodynamics and, 55
    saralasin, 55, 62
    teprotide, 55
Anoxia
  carbon monoxide neuropathology and, 543
Antioxidants
  biliverdin, 517, 522
  Carolina rinse solution and, 327
  estradiol, 483, 487–88, 496, 500
  vitamin E, 488
Antisense RNA blockage, 124
Apoptosis, 93, 243–44
  mechanism of, 244
Arachidonic acid, 182, 220
  release
    mGluRs and, 220
L-Arginine, 340, 350–55
  nitric oxide synthase and dimer assembly and, 350–51
Arsenic
  biotransformation of, 398–419
    folic acid derivatives and, 413
    genetic polymorphism and, 403–5
  methylated arsenic species, 400–19
    dimethylarsonic acid (DMA), 400–2, 408, 412–19
    diversity, 402–5
    evolutionary significance, 402–5
    monomethylarsonic acid (MMA), 400
  methyltransferases, 397–98, 412–15
    genotoxicity, 414–15
    intermediates, 412–13
    porphyrin profiles, 415
    protein binding and, 413–14
    uptake, 414

toxicity, 397–416
cancer and, 398, 412
tolerance and, 411–12
Arsenite biotransformation, 403
Arsine, 398, 410–11
toxicity, 410–11
Asthma
passive smoking and, 29–30, 45–47
Atherosclerosis, 477–503
estrogen-mediated inhibition of, 477–85, 493–97, 501–2
cholesterol levels in plasma and tissue and, 480–85
estrogen replacement and, 478–79, 501–2
nitric oxide and, 493–97
fatty streak development, 485–89, 495–96
foam cell formation, 485–89, 495–96
lipoprotein transport, retention, and modification, 484–86
lipoprotein uptake, 485, 495–96
monocyte adherence, migration, and differentiation, 485, 495–96
gender differences in incidence of, 477–79
hypercholesterolemia and, 480–85
lesions, 480
advanced atherosclerotic, 497–98
formation of fibrofatty, 496–97

B

Behavior
drug-taking, 451–72
model for, 458
(See also Compliance)
Benz(othi)azepines, 361, 364, 371–74, 387–91
binding site
access pathway to, 373
mutational analysis of, 374
receptor site
biochemical localization of, 373–74
structure and selectivity, 371–72
voltage and state dependence of Ca^{2+} channel block, 371, 373
Bilirubin, 518
Biliverdin, 518, 522
Biliverdin reductase (BVR), 518, 536
Blood pressure regulation
renal renin-angiotensin system blockage and, 57–58
renin-angiotensin system and, 53–58, 66
Brain-derived neurotrophic factor (BDNF), 239, 242–43, 246, 248–51
Bruton tyrosine kinase, 190

C

Caffeine, 12–13
Calcium ATPase pump, 186
Calcium channel blockers
benz(othi)azepines, 361, 364, 371–74
dihydropyridines, 361, 364, 371–91
phenylalkylamines, 361, 364–73
[See also Benz(othi)azepines, Dihydropyridines, Phenylalkylamines]
Calcium channels
chimeric
identification of dihydropyridine binding regions using, 379–82
$G_{\beta\gamma}$ subunit and, 181–93
L-type, 361–91
diversity of cellular responses, 362
domain-interaction model for allosteric modulation of, 390
smooth-muscle contraction and, 361, 387–91
transmembrane segments IIIS6 and IVS6, 387–91
Calcium homeostasis
disruption of hepatotoxicity and, 93
Calmodulin (CaM), 340–53
nitric oxide synthase and binding sites for, 340, 354
Cancer
arsenic toxicity and, 398, 412
chemotherapeutics
farnesyltransferase inhibitors, 143–61
Captopril, 56, 62–63
Carbon monoxide
generation
heme oxygenase system and, 517–45
similarity to nitric oxide generating system, 529–30
roles
in cardiovascular system, 541–42
in immune system, 542–43
in LTP and, 539–41
in nervous system, 539–41
as signal molecule for generation of cGMP, 530–33, 537–39
toxicity, 543–44
Carcinogenesis
pulmonary, 29–30, 33–35
Cardiotrophin-1, 241
Cardiovascular disease
estrogen and prevention of, 477–503
estrogen replacement and, 470–79
Cardiovascular hypertrophy
renin-angiotensin system tissues and, 54
Carolina rinse solution
liver transplantation therapy and, 327, 333–35
Cell death, 93, 243–44
cGMP (See Cyclic GMP)
Cholinsterase, 5, 8
Chronic obstructive pulmonary disease
passive smoking and, 30, 35–36
Cigarette sidestream smoke, 29–47
adverse effects on pre- and postnatal development, 29, 36–47
Clara cells and, 39–41
cytochrome P450 expression and, 38, 40
enzyme activity in bronchial tree, 39–41
hepatic EROD activity, 39
intrauterine growth retardation, 29, 36–37
NADPH reductase protein expression and, 38, 40
carcinogenic potency, 33–35
cardiovascular changes, 36
lung function changes, 41–47
effector cell and, 43
hyperresponsiveness to serotonin, 41
rapidly adapting receptors and, 45
pulmonary effects, 35–36
(See also Environmental tobacco smoke, Passive smoking)
Ciliary neurotrophic factor (CNTF), 241–43, 251, 253–55
amyotrophic neurotrophic

factor therapy, 245–46
Clara cells
enzyme activity in bronchial tree
cigarette sidestream smoke and, 39–41
Clinical trials
compliance issues and, 451–52, 468–72
sample size and power
intention to treat analysis, 469–71
new drug applications and, 471
CLIX program, 78
Cohn, Edwin J., 7
Colony-stimulating factor (CSF-1), 495
Compliance, 451–72
clinical trials and, 451–52, 468–72
intention to treat analysis, 469–71
compliance indices, 456
cost of, 471
defined, 452–54
method effectiveness, 453, 470–71
use effectiveness, 453, 470–71
directly observed therapy, 455
drug development and, 451–72
exposure-response relationship, 465–68, 472
measuring, 453–55
monitoring
disclosure and, 460
dosing frequency and, 462–63
duration, 462
electronic, 453–72
patient population variation, 458–60
pharmacokinetic parameters and, 464
Computational alchemy, 81–85
Computational chemistry, 71–86
Congestive heart failure
renin-angiotensin system tissues and, 54
Covalent binding, 91–109
hepatotoxicity and, 91–97
nephrotoxicity and, 98–99
Cyclic AMP accumulation
mGluRs and, 218–19
Cyclic AMP responsive elements, 423
Cyclic GMP
accumulation
mGluRs and, 219
carbon monoxide and generation of, 530–33, 537–45
heme oxygenase system and, 517
Cyclic GMP–dependent activities
carbon monoxide regulation of, 517, 530–33
Cyclic guanine monophosphate (See Cyclic GMP)
Cyclosporin A, 298, 310–11
CYP2C genes, 287–88
CYP2D genes, 269–70, 279–84
genetic variability, 279–84
functional alleles, 282–84
null alleles, 280–82
Cytochromes P450
cigarette sidestream smoke and, 38, 40
hepatotoxicity and
acetaminophen-induced, 92–96
ethanol and, 103–4
halothane and, 99
tienilic acid and, 102–3
isozymes
dibrisoquine-sparteine polymorphism and, 269, 277–86
mephenytoin polymorphism and, 269, 286–88

D

Desmethyoxyverapamil, 364–71
Dibrisoquine-sparteine
polymorphism of drug oxidation, 269–70, 277–86
interethnic variability and evolution, 284–86
molecular mechanism, 278–84
CPP2D genes, 269–70, 279–84
genetic variability, 279–84
risk factor for certain diseases, 278
therapeutic consequences, 278
Diclofenac
hepatotoxicity and, 105, 107
protein adduct, 106
Dihydralazine, 102–3
Dihydropyridines (DHPs), 361, 364, 371–91
agonist and antagonist receptor sites, 386–87
identification of access pathway, 375–78
individual amines acid residues and binding of
site-directed mutagenesis studies of, 382–84
localization of receptor site, 378–79
molecular mechanism of high-affinity L-type Ca^{2+} channels and, 384–86
voltage and state dependence of action of, 374–75
Dioxin receptors
hsp90-based chaperone system and, 297–98, 303, 309
Dioxin toxicity
transgenic mouse model, 136
Directly observed therapy (DOT), 455
Docking, 71–75
structural databases
lead compound generation and, 74–75
Drinking water
arsenic in, 397–98
Drug abuse, 14–20, 26
heroin, 14–20
methodone treatment for, 14–20
Drug acetylation
polymorphism (See Acetylation polymorphism)
Drug design, structure-based (See Structure-based drug design)
Drug development
compliance and, 451–52
electronic monitoring of, 453–54
Drug metabolism, 269–89
Dynorphin, 8, 16–17, 21
discovery of, 8
peptides, 21

E

Embryonic stem cell technology, 121, 126–30
Enalkiren, 63
Endothelial cells
liver reperfusion injuries and, 327–30, 335
Endothelium-dependent hyperpolarizing factor (EDHF), 500
Endothelium-derived relaxing factor (EDRF), 493
Environmental tobacco smoke
as carcinogen, 29–30
carcinogenic potency, 33–35
effects on Clara cells, 39–41
intrauterine growth retardation and, 29, 36–37
mainstream smoke, 32, 41
measuring exposure of nonsmokers to, 32

pulmonary effects, 35–36
sidestream smoke, 29, 32–47
(See also Cigarette sidestream smoke, Passive smoking)
Epidermal growth factor (EGF), 241, 253
Epinephrine
early research, 4
Estradiol, 483, 487–88, 496, 500
Estrogens, 477–503
altered vasomotion and, 498–502
therapeutic implications of, 501–2
antioxidant effects of, 477, 486–89
atherosclerosis and, 477–503
cholesterol levels in plasma and tissues, 480–85
formation of fibrofatty lesion, 496–97
gender differences in incidence of, 477–79
equine, 501–2
estrogen replacement therapy, 477–79, 501–2
progestins and, 497, 501–2
Ethanol
alcoholic liver disease and, 103–4, 106
liver grafts and use of, 327, 333, 335
Ethoxyresorufin-O-dealylase, 38–39
Euro-Collins solution, 329
Excitotoxicity
mGluRs and reducing, 225
Exposure-response relationships
noncompliance and, 465–68, 472

F

Farnesylation
G_γ subunit and, 174–75
Farnesyl-protein transferase (FPTase), 143–61
Farnesyltransferase inhibitors, 143–61
efficacy against *ras*-transformed cells, 153–54
selectivity for tumor cells, 157–58
structural diversity, 149–51
Ferrochelatase, 518
Fibroblast growth factor (bFGF), 241, 251–52
acidic (aFGF), 241
FK506, 298, 310–11
Flavoproteins
nitric oxide synthases and, 339–55
Folic acid
arsenic biotransformation and, 413
Free-energy calculation
perturbation method, 71, 83
thermodynamic integration method, 83
Free-radical immunoassay, 20
Free radicals, 244, 517
nitric oxide, 392, 493–97, 517–30

G

Gaddum, John, 7–8
GDP, 169
Geldanamycin, 308, 315–16
Gene targeting, 121–37
design of vectors, 126–29
embryonic stem cell technology, 121, 126–30
(See also Transgenic technology)
Genetic polymorphisms, 269–89
acetylation, 269–77
clinical relevance, 271
interethnic variability and evolution, 276-77
molecular mechanism, 271–76
NAT1, NAT2, 269–70, 272–76
defined, 270
dibrisoquine-sparteine, 269–70, 277–86
clinical relevance, 278
cytochrome P450 *CYP2D* genes, 269–70, 279–84
interethnic variability and evolution, 284–86
molecular mechanism, 278–84
mephenytoin, 269–70, 286–88
clinical relevance, 286–87
interethnic variability and evolution, 288
molecular mechanism, 287–88
Geranylgeranylation, 143, 147, 158–59, 174–75
G_γ subunit, 174–75
Geranygeranyl-protein transferase types I and II, 148
Glial cell–derived neurotrophic factor (GDNF), 241, 243, 248–56
Parkinson's disease and, 248–50
Glycine, 327, 333–35
Carolina rinse solution and, 327, 333–35
Glucocortical response element (GRE), 524
Glutamate receptors
ionotropic glutamate receptors (IGluRs), 205, 225
metatropic glutamate receptors (mGluRs), 205–27
G protein–coupled receptors, 205–27
G protein–linked receptors, 167–93
GDP, 169
GTP, 169
olfactory
visual syste
rhodopsin,
G proteins, 167-
$\beta\gamma$ subunits
hsp90 chaperoning
316–18
G protein signal transducti
system, 167–93
effectors, 167, 178–90
specificity of, 180
G_α subunits, 167, 169, 176–78
$G_{\beta\gamma}$ subunits, 167–93
β and γ assembly, 173–74
β and γ interactions, 173
effector targets, 178–90
lipid modification, 174–75
localization, 176
phosphorylation, 175–76
proteins interacting with, 191–93
structure, 169–73
in vesicular traffic, 187–88
WD-repeat, 170
GRID program, 78
GROW method, 76–77
Growth factors
epidermal (EGF), 241, 253
fibroblast(bFGF), 241, 251–52
acidic (aFGF), 241
insulin-like (IGF), 241, 246, 248, 252–53
nerve (NGF), 239, 243, 247–48, 253–57
non-neurotrophin, 242
transforming (TGF), 240–41
GTP, 169
Guanine nucleotide diphosphate (GDP), 169
Guanine nucleotide binding proteins (See G proteins)
Guanine nucleotide triphosphate (GTP), 169
Guanosine monophosphate, cyclic (See cGMP)
Guanylate cyclase, soluble (See Soluble guanylate cyclase)

H

Halothane, 91, 99–102
  hepatitis and, 99–102
  hepatotoxicity and, 99–102
  protein adducts, 99–102
Heat-shock nuclear factor, 524
Heat-shock protein (HSP), 297–318, 518
  (See also Heme oxygenase-1)
Heat-shock protein (hsp) 90–based chaperone system, 297–318
  dioxin receptors and, 297–98, 303, 309
  G protein $\beta\gamma$ subunit and, 316–18
  hsp heterocomplex assembly system, 298–302
    components, 299–300
    mechanism, 300–2
  immunophilins, 297–98, 309–12
    cyclosporin A–binding protein, 311
    FK506-binding proteins, 310–11
    functions, 312
    immunophilin binding site, 311–12
  MAP kinase system and, 298, 307, 313–15
  steroid receptors and, 297–98, 303–18
    hormone-binding domain, 303–4
    receptor trafficking, 307–9
    required for normal signal transduction, 305–7
    steroid binding site, 304–5
Hematin, 520
Heme
  free, 519
  ligand interactions, 519–45
Heme oxygenase (HO) system, 517–45
  isozymes of
    carbon monoxide produced by, 517–45
    molecular properties of, 522–24
    reciprocity with nitric oxide–generating system, 533–36
    regulation, distribution, and development, 524–29
Heme oxygenase-1 (Heat-shock protein) and -2, 517–45
  distribution
    in brain, 525–27
    in cardiovascular system, 528
    in liver, 528–29
    in reproductive system, 528
Hemeprotein
  nitric oxide synthases and, 339–55
    promotion of dimer assembly of, 352
Heparin-binding neurotrophic factor (= pleotrophin), 241
Hepatic necrosis
  acetaminophen-induced, 92-94
Hepatic parenchymal cells, 329
Hepatitis
  dihydralazine and, 102–3
  halothane and, 99–102
Hepatotoxicity
  acetaminophen-induced, 91–97
  amodiaquine and, 98
  butylated hydroxytoluene and, 97
  diclofenac and, 105–7
  ethanol and, 103–4, 106
  glutathione protective against, 92
  halothane and, 91, 99–102
  methapyrilene and, 97
  possible mechanisms of, 93
Heregulins, 241
Heroin addiction, 14–20
  methadone treatment for, 14–20
HIV protease
  crystallographic structures of, 83–84
  nonpeptide-based inhibitors design of, 72–74, 78
HOOK program, 76
Hormone replacement therapy, 478–79, 501–2
Hsp90 (See Heat-shock protein 90–based chaperone system)
Human umbilical vein endothelial cell (HUVEC), 490, 497
Hyaluronic acid, 85–86
3-Hydroxy-3 methylglutaryl coenzyme A reductase (HMG CoA reductase), 482
Hypercholesterolemia, 480
Hypertension, 54
  renin-angiotensin system tissues and, 54
Hypertension
  mGluRs and regulation of, 227

I

Immunophilins, 297–98, 309–12
  hsp90-based chaperone system binding site, 311–12
    cyclosporin a–binding protein, 311
    FK506-binding proteins, 310–11
    functions, 312
Inhalation anesthesia, 10–11
Insulin-like growth factor (IGF), 241, 246, 248
  acute nervous system injury and, 251
  amyotrophic lateral sclerosis therapy, 246
Intention to treat (ITT) analysis compliance and, 469–71
Intercellular adhesion molecule 1 (ICAM-1), 490
Intermediate density lipoproteins (IDLs), 481–85
International Narcotic Research Conference, 15
Inward rectifier G protein–gated K^+ channel, 181–83
Ionotropic glutamate receptors (iGluRs), 205
Iron-responsive elements, 535
Ischemic stroke
  neurotrophic therapy for, 251–52

K

Kidney
  renin-angiotensin system of, 53–66
    renal hemodynamics and, 55
Krayer, Otto, 8–9
Kuppfer cells, 93, 327–35
  activation of
    hepatotoxicity and, 93
    liver reperfusion injuries and, 327–30
  inflammatory mediators released by, 329–30
    "cytokine storm," 329–30

L

L-Cysteine-sulfinic acid (L-CSA), 220
Lead compound discovery
  3-D database methods, 78–79
  docking from structural databases and, 74–75
  generation from fragment methods, 75–78
    GROW method, 76–77
    HOOK program, 76
    LUDI algorithm, 76
    MCSS program, 75–76
    Monte Carlo De Novo Ligand Generator, 77
    SPROUT program, 77–78

molecular visualization and modeling of, 72–74
simplified potential energy functions and, 79–81
Lead compound refining and reengineering, 81–86
alchemical free-energy changes, 82–85
determination of positions of tightly bound waters, 85–86
perturbation method of free-energy calculation, , 83
thermodynamic integration method, 83
Lecithin cholesterol acyl transferase (LCAT), 481–82
Leptin
metabolism and, 444, 446
Leucine, isoleucine, valine binding protein (LIVBP), 215–17
Leukemia inhibition factor (LIF), 126
Leukocyte inhibitory factor/cholinergic differentiation factor, 241
Lipid metabolism
β_3-adrenoreceptor and, 421, 431–47
Lisinopril, 61, 62
Liver transplantation therapy
Carolina rinse solution and, 327, 333–35
endothelial cell killing and, 328–30, 335
graft failure and, 332–33
Kupffer cell activation and, 328–35
pH paradox and, 330–31
reperfusion injury and, 327–35
Lipoprotein(a), 483
Lipoproteins
high-density (HDL), 477, 481–85, 489
intermediate density (IDL), 481–85
low-density (LDL), 477, 481–95
estrogen and prevention of oxidation of, 477
oxidation of, 488–89
role of nitric oxide in oxidation of, 495
very low density(VLDL), 477, 481–85, 489
Long-term potentiation
carbon monoxide's role in, 539–41
Losartan, 61–63
LUDI algorithm, 76
Lung cancer
passive smoking and, 29–30, 33–35
Lysine, arginine, ornithine binding protein, 216

M

Macrophage colony-stimulating factor (MCSF), 492
MAP (mitogen-activated protein) kinase, 217
MAP kinase cascade, 153
$G_{\beta\gamma}$ subunit and, 188–89
MAP kinase system, 298, 307, 313–15
Medullipin, 57
Memory impairment
mGluR ligands and, 226
Menopause, 478, 501–2
Mephenytoin polymorphism, 269–70, 286–88
clinical relevance, 286–87
interethnic variability and evolution, 288
molecular mechanism, 287–88
CYP2C genes, 269–70, 287–88
CYP2C19 alleles, 287–88
Metabotropic glutamate receptors (mGluRs), 205–27
clinical potential, 225–27
antiepileptic, 226
cognitive enhancement and, 226
hypertension and, 227
movement disorders and, 226
pain and, 227
reducing excitotoxicity with, 225
cloned, 206–27
glutamate binding site, 215–16
G-protein coupling, 216–17
human homologues, 208
intramolecular transduction, 217
pharmacology, 210–14
splice variants, 206–8
structure, 214–15
transduction mechanisms, 208–10
regulation of ion channels and cell excitability, 220–22
potassium channel modulation, 220–21
voltage-dependent calcium channel modulation, 221–22
regulation of second messengers, 218–20
adenylcyclase inhibition, 218
cAMP accumulation, 218–19
cGMP accumulation, 219
phosphoinositide hydrolysis, 218
regulation of synaptic transmission, 222–25
Metallothionein, 123
Methadone, 14–20
long-acting, 17–18
Methapyrilene, 97, 106
Methoxyverapamil, 364–71
1-Methyl-4-phenylpyridinium (See MPP^+)
Methyltransferase
arsenite, 397–98, 412–15
genotoxicity, 414–15
intermediates, 412–13
porphyrin profiles, 415
protein binding, 413–14
uptake, 414
mGluRs (See Metabotropic glutamate receptors)
Military medicine, 5–6
Mitochondrion
as organelle of acetaminophen-induced hepatotoxicity, 94–95
Mitogen-activated protein (See MAP)
Molecular biology
early, 11–12
Molybdate, 307–8
Monocyte chemoattractant protein (MCP-1), 492–94
Monte Carlo De Novo Ligand Generator, 77
Movement disorders
mGluR ligands and treatment of, 226 MPP^+, 248
MPTP, 249
Multiple sclerosis
neurotrophic therapy for, 252–53
insulin-like growth factor 1, 252–53
Muscarinic (acetylcholine)-gated K^+ channel
$G_{\beta\gamma}$ subunit and, 181–83

N

NADPH
nitric oxide synthases and binding sites for, 340–55
NADPH-cytochrome P450 reductase, 341, 522
NADPH reductase protein expression
cigarette sidestream smoke and, 38, 40

NAT2 gene
genetic variability, 273–76
decreased function alleles, 273–75
functional characterization of mutant alleles, 275–76
locus, 269–70, 272–76
Nephrotoxicity, 98–99
Nerve growth factor (NGF), 239, 243, 247–48, 253–57
nervous system injury treatment, 251–52
sensory neuropathy treatment and, 247–48
Neuregulins, 241
Neurotrophic factors, 239–57
brain-derived (BDNF), 239, 242–43, 246, 248–51
ciliary (CNTF), 241–43, 251, 253–55
glial cell-derived (GDNF), 241, 243, 248–56
heparin-binding, 241
long-term potentiation and, 243
neuroprotection mechanisms, 243–44
pharmacology, 253–57
intracerebral administration, 254–55
small molecule mimetics, 255–57
physiologic function, 242–43
therapeutics, 244–53
acute nervous system injury, 251–52
Alzheimer's disease, 250–51
amyotrophic lateral sclerosis, 244–47
ischemic stroke, 251–52
multiple sclerosis, 252–53
Parkinson's disease, 248–50
sensory neuropathy, 247–48
Neurotrophin-3 (NT3), 239, 242, 246, 248, 251, 254
Neurotrophin-4/5 (NT4/5), 239, 246–49, 251
New drug applications, 471
Nicotine, 32–33
Nicotine-derived nitrosamine ketone (NNK), 40
Nitric oxide (NO), 392, 493–97, 517–30
activity
reciprocity with heme oxygenase system, 533–36
regulation of, 517–21
similarities to carbon monoxide generating system, 529–30
soluble guanylate cyclase activation by, 520
estrogen-mediated inhibition of atherosclerosis and, 493–96
monocyte adherence and migration and, 493–95
role in oxidation of low-density lipoprotein, 495
Nitric oxide synthase (NOS), 339–55, 494–96, 518, 520, 534, 540
bi-domain organization, prosthetic group, and substrate binding sites, 340–43
dimeric, 346–55
dimer assembly and L-arginine analogs, 350–51
dimeric interaction and heterodimer formation, 351–52
dissociation and unfolding of, 346–48
heme-containing monomers and, 350
heme-free NOS monomers and, 348–50
endothelial (eNOS), 494
expression in cytokine-activated cells, 352–54
heme oxygenase system and, 518, 520, 534, 540
reductase and oxygenase domains, 343–46
catalysis of mixed-domain system, 345–46
catalytic properties of isolated domains, 344–45
oxygenase domain active site, 344
S-Nitroso-*N*-acetyl penicillamin, 497
Non-insulin-dependent diabetes (NIDDM)
β_3-adrenergic receptor and, 421, 431–32, 438–40, 442–46
polymorphism of human, 444
Non-neurotrophin growth factors, 242
Noradrenaline receptor, 423
Norepinephrine
early research, 7

O

Obesity
β_3-adrenergic receptor and regulation of, 421, 431–32, 438–40, 442–46
polymorphism of human, 44
heredity and, 444, 446
leptin receptor and, 446
OncoMouse models of dioxin toxicity, 136
Opioids
dynorphin, 8, 16–17
endogenous opioid peptide acupuncture and, 23
receptors, 14–16
Oxidation
low-density lipoprotein estrogen and prevention of, 477, 486–89
Oxidative stress, 93–98, 244, 517–32, 544
heme oxygenase and, 517–32, 544
heme production and, 532
nephrotoxicity and, 98
hepatotoxicity and, 93
sudden infant death syndrome (SIDS) and, 544

P

Parkinson's disease, 241, 248–50, 254
GDNF and 241, 248–50
neurotrophin therapy for, 248–50
Passive smoking
asthma and, 30
cardiovascular disease and, 30, 36
children and
lung function in, 41–47
respiratory effects in, 29–47
chronic obstructive pulmonary disease and, 30, 35–36
(See also Cigarette sidestream smoke, Environmental tobacco smoke)
Perindopril, 64
Periodate-oxidized adenosine, 398
Periplasmic binding proteins (PBP), 215–17
PH domains, 191–93
Phenolphthalein analogs, 75
Phenylalkylamines, 361, 364–71, 387–91
high-affinity binding, 369–71
mutations in tranmembrane segment IVS6, 369–70
receptor site
access pathway to, 366–67
biochemical localization of, 367
mutational analysis of, 367–69
structure and selectivity, 364

verapamil, 364–71
voltage and state dependence of Ca^{2+} channel block, 364–66
Phosducin, 191
Phosphoinositide hydrolysis, 209, 218
Phosphoinositide-3 kinase
$G_{\beta\gamma}$ subunit and, 189–90
Phospholipase
A, 220
A_2
$G_{\beta\gamma}$ subunit and, 183
C
hydrolysis, 209
Cβ
$G_{\beta\gamma}$ subunit and, 183–85
D, 220
novel metabotropic receptor coupled to, 220
Pleotrophin (= heparin-binding neurotrophic factor), 241
Porphyrin, 519–30
ring, 519
Potassium channels, 181–83, 220–21
mGluRs and modulation of, 220–21
muscarinic (acetylcholine)-gated, 181–83
Progestins
with estrogen replacement therapy, 497, 501–2
Protein adducts, 91
xenobiotic
acetaminophen, 93–97
butylated hydroxytoluene, 97
halothane, 99–102
in kidney, 98–99
methapyrilene, 97
tienilic acid, 102–3, 106
Protein chaperone (See Heat-shock protein 90–based chaperone system)
Protein folding
heat-shock protein 90–based chaperone system and, 297–98
Protein prenylation, 145–61
enzymes that catalyze, 148
p75-NGFR, 239–40

R

Raloxifene response element, 491
Ramipril, 65
Ras
exchange factor
$G_{\beta\gamma}$ subunit and, 190
protein prenylation reactions, 146
ras-induced cell transformation
farnesyl-protein transferase and, 144–61
ras oncogenes
farnesyltransferase inhibitors and, 143–61
Receptor kinases
$G_{\beta\gamma}$ subunit and, 186–87
Renin-angiotensin system (RAS)
tissues, 53–66
access to site of angiotenin II production, 64–65
blockade by ACE inhibitors, 53–57
cardiovascular hypertrophy and, 54
contractility and, 61–62
growth and, 62–63
hypertension and, 54
in kidney, 53–66
sodium reabsorption, 53
partitioning of renal, 59–60
renin inhibitors, 63–65
Reperfusion injury
liver transplantation and, 327–35

S

S-adenosylmathionine, 398
Saralasin, 55, 62
Sex-hormone–binding globulin, 486
Signal transduction, 167–93
G protein (See G protein signal transduction system)
heat-shock protein 90 and, 297–318
(See also Heat-shock protein 90–based chaperone system)
Smoking
passive (See Passive smoking; see also Cigarette sidestream smoke, Environmental tobacco smoke)
Smooth muscle contraction
L-type Ca^{2+} channels and, 361–91
S-nitroso-*N*-acetyl penicillamin (SNAP), 497
Sodium nitropruside, 497
Sodium reabsorption, 53
Soluble guanylate cyclase (sGC), 518–21, 537
activation by nitric oxide, 520
regulation by heme oxygenase system, 530
SPROUT program, 77–78
Steroid receptors
heat-shock protein 90 chaperones and, 297–98, 303–18
hormone binding domain, 303–4
receptor trafficking, 307–9
required for normal signal transduction, 305–7
steroid binding site, 304–5
immunophilin chaperones and, 298, 309–12
Structure-based drug design, 71–86
lead compound discovery, 71–81
3-D database methods, 78–79
docking from structural databases and, 74–75
generation from fragment methods, 75–78
molecular visualization and modeling of, 72–74
simplified potential energy functions and, 79–81
lead compound refining and reengineering, 81–86
alchemical free-energy changes, 82–85
determination of positions of tightly bound waters, 85–86
perturbation method of free-energy calculation, 71, 83
thermodynamic integration method, 83
Sulisobenzone, 75
Superoxide dismutase, 245, 494
Synaptic transmission
mGluRs and, 205, 222–25
presynaptic autoreceptors at glutamatergic synapes, 222–23
Systemic inflammatory response syndrome, 329–30
Syva, 19–20

T

Tamoxifen, 501
Teprotide, 55
Tetradecapeptide, 62
Tetrahydrobioterin (H4 biopterin)
nitric oxide synthases and, 339–55
promotion of dimer assembly, 352
Thermogenesis

β_3-adrenergic
receptor–induced, 421, 431–40
Thymidylate synthase, 84
inhibitors, 74–75
Tienilic acid, 102–3, 106
Transforming growth factor-α, 240–41
Transgenic mice (See Transgenic technology, transgenic animal models; see also Gene targeting, OncoMouse model of dioxin toxicity)
Transgenic technology
embryonic stem cell isolation, 121, 125–30
gene targeting, 121–30
pharmacologic applications, 130–37
cancer, 135–36
cardiovascular, 131–33
endocrine system, 134–35
nervous system, 133–34
toxicology, 136
pronuclear DNA injection, 122–30
antisense RNA blockage, 124–25
gene regulation, 125
inducible promotor systems, 123
transgenic animal models, 120–21, 125–37
β-adrenergic receptor system, 131–33
embryonic stem cells, 121, 126–30
hormone receptors, 134–35
lipoprotein metabolism, 131–33
peptide hormones, 134–35
receptor activation, 133–34
renin/angiotensin system and, 131–32
tumor immunotherapy, 135–36
(See also Gene targeting)
Transplantation
liver reperfusion injury after liver preservation, 327–35
Trichloroethylene, 91, 104–6
protein adducts, 106
Trk—type protein kinase receptor, 239, 242, 246
Trypanothione, 405–6
Tumorigenesis, 143
Tumor necrosis factor, 490, 495, 497
Tumor necrosis factor-α, 329, 332, 334

U

University of Wisconsin solution, 327–28

V

Valsartan, 57
Vascular cell adhesion molecule-1 (VCAM-1), 489–94
Vasodilation
estrogens and promotion of, 477
Voltage-gated ion channels, 181–83, 361–91
(See also Calcium channels, Potassium channels)
Verapamil, 364–71
Vinculin, 176

W

WD-repeat, 170, 174

X

Xenobiotics, 91–109

Z

Zaffaroni, Alex, 19–20
Zankiren, 63
Zidovudine
patient compliance and, 456–57, 460

CUMULATIVE INDEXES

CONTRIBUTING AUTHORS, VOLUMES 33–37

A

Alexander RW, 36:281–306
Amidon GL, 34:321–41
Angle CR, 33:409–34
Aposhian HV, 37:397–419
Augustine GJ, 36:659–701

B

Barrett JC, 36:573–96
Bellamy WT, 36:161–83
Bennett CF, 36:107–29
Benowitz NL, 36:597–613
Bevan JA, 34:173–90
Bilsky EJ, 36:379–401
Black J, 36:1–33
Blaschke TF, 37:451–75
Bowery NG, 33:109–47
Boyer JL, 35:541–79
Brater DC, 33:435–65
Bray TM, 34:91–115
Briggs JM, 37:71–90
Briving C, 35:277–305
Bunzow JR, 33:281–307
Burchiel SW, 36:131–59
Burns ME, 36:659–701
Burt SK, 36:545–71

C

Catterall WA, 37:361–96
Chan P-C, 34:41–67
Chang LW, 34:41–67
Chao AC, 35:257–76
Chaudhuri G, 35:165–94; 37:477–515
Chen AY, 34:191–218
Civelli O, 33:281–307
Claghorn JL, 33:165–77
Clapham DE, 37:167–203
Clarkson TW, 33:545–71
Collman GW, 36:573–96
Conn PJ, 37:205–37
Cordell B, 34:69–89
Corey JL, 34:219–49
Cory-Slechta DA, 35:391–415
Coyle JT, 36:83–106
Cronstein BN, 35:449–62
Crooke ST, 32:329–76; 36:107–29
Croxatto HB, 36:47–81

D

Dahl AR, 33:383–407
Davila DR, 36:131–59
Davis B, 35:341–68
DeBello WM, 36:659–701
De Mey JGR, 35:501–39
Dessauer CW, 36:461–80
Dray A, 36:253–80
Dunham EW, 37:53–69

E

Eaton DL, 34:135–72
Edwards G, 33:597–637
Elion GB, 33:1–23
Emmerson KS, 34:91–115
Erickson JW, 36:545–71
Esbenshade TA, 34:117–33
Evans CJ, 36:379–401
Exton JH, 36:481–509

F

Fan A, 35:341–68
Felten DL, 35:417–48
Fukuto JM, 35:165–94
Fung BK-K, 33:201–41
Furchgott RF, 35:1–27

G

Gallagher EP, 34:135–72
Gardner P, 35:257–76
Gibbs JB, 37:143–66
Gilman AG, 36:461–80
Gnegy ME, 33:45–70
Goldstein A, 37:1–28
Gonzalez FJ, 35:369–90
Grandy DK, 33:281–307
Griendling KK, 36:281–306
Gudermann T, 36:429–59

H

Halmes NC, 37:91–117
Halpert JR, 35:29–53
Hankinson O, 35:307–40
Harden TK, 35:541–79
Harman AW, 35:129–44
Hefti F, 37:239–67
Henrion D, 34:173–90
Hersey S, 35:277–305
Hieble JP, 33:243–79
Hockerman GH, 37:361–96
Hollister LE, 33:165–77
Holsapple MP, 36:131–59
Homeister JW, 34:17–40
Howd R, 35:341–68
Howlett AC, 35:607–34
Hoyer PB, 36:307–31
Hsia SMT, 34:41–67
Hsieh L-L, 34:41–67
Huff J, 34:343–72; 36:573–96

J

Joad JP, 37:29–52
Johnson BD, 37:361–96
Jordan VC, 35:195–211

K

Kalkbrenner F, 36:429–59
Kaminski NE, 36:131–59
Karras JG, 36:131–59
Kastrissios H, 37:451–75
Kopin IJ, 33:467–95
Korzekwa KR, 35:369–90

L

Lai J, 36:379–401
Lake BG, 35:483–507
Laskin DL, 35:655–77
Lassègue B, 36:281–306
Lazo JS, 35:635–53
Ledbetter JA, 36:131–59
Lee HJ, 34:321–41
Lefer AM, 33:71–90
Lefer DJ, 33:71–90
Lemasters JJ, 37:327–38
Le Moal M, 36:359–78
Lester HA, 34:219–49
Lewis JL, 33:383–407
Li C, 36:185–201
Liehr JG, 36:203–32
Liu LF, 34:191–218
Lucchesi BR, 34:17–40

Lucier G, 34:343–72
Lukas SE, 36:333–57

M

Macdonald RL, 35:463–82
Madden KS, 35:417–48
Mager S, 34:219–49
Maines MD, 37:517–54
Marrone TJ, 37:71–90
Marton LJ, 35:55–91
Masaki T, 35:235–55
Maxwell MJ, 35:129–44
McCammon JA, 37:71–90
Meyer UA, 37:269–96
Miljanich GP, 35:707–34
Minneman KP, 34:117–33
Mirsalis JC, 35:145–64
Mombouli J-V, 35:679–705
Monforte JA, 35:125–44
Murray MD, 33:435–65
Myers MG Jr, 36:615–58

N

Nathan L, 37:477–515
Neal RA, 36:35–46
Neer EJ, 37:167–203
Nicholas RA, 35:541–79
Nichols AJ, 33:243–79

O

Oguri K, 34:251–79
Olah ME, 35:581–606
Oliff A, 37:143–66
Oliyai R, 33:521–44
Ondetti MA, 34:1–16

P

Pechnick RN, 33:353–82
Pegg AE, 35:55–91
Pendino KJ, 35:655–77
Peoples RW, 36:185–201
Peterson BZ, 37:361–96
Pettit DL, 36:659–701
Piazza PV, 36:359–78
Pin J-P, 37:205–37
Pinkerton KE, 37:29–52
Pitt BR, 35:635–53
Polson JB, 36:403–27
Porreca F, 36:379–401
Pratt WB, 37:297–326
Pumford NR, 37:91–117

Q

Quick MW, 34:219–49

R

Radić Z, 34:281–320
Ramachandran J, 35:707–34
Rand MJ, 33:25–44
Regunathan S, 36:511–44
Reis DJ, 33:309–52; 36:511–44
Ricaurte GA, 33:639–77
Richman DD, 33:149–64
Robbins A, 36:47–81
Rock DM, 35:463–82
Rockhold RW, 33:497–520
Ruffolo RR Jr, 33:243–79

S

Sabol KE, 33:639–77
Sachs G, 35:277–305
Sanders VM, 35:417–48
Schatz AR, 36:131–59
Schieven GL, 36:131–59
Schultz G, 36:429–59
Schweizer FE, 36:659–701
Seiden LS, 33:639–77
Shin JM, 35:277–305
Simonian NA, 36:83–106
Sipes IG, 36:307–31
Smits JFM, 35:501–39
Snyder SH, 35:213–33
Spitz IM, 36:47–81
Stadel J M, 33:243–79
Stella VJ, 33:521–44
Stiles GL, 35:581–606
Strada SJ, 36:403–27
Strosberg AD, 37:421–50
Struijker-Boudier HAJ, 35:509–39
Stuehr DJ, 37:339–59
Sunahara RK, 36:461–80

T

Taylor P, 34:281–320
Thomas HA, 33:91–108
Thurman RG, 37:327–38
Tolstoshev P, 33:573–96
Tritscher A, 34:343–72

U

Urban L, 36:253–80

V

Vanderah TW, 36:379–401
Vanhoutte PM, 35:679–705

W

Wagner JA, 35:257–76
Wahlestedt C, 33:309–52
Wallmark B, 35:277–305
Wang CC, 35:93–127
Wei ET, 33:91–108
Wei L-N, 37:119–41
Weight FF, 36:185–201
Weissmann G, 35:449–62
Weston AH, 33:597–637
White MF, 36:615–58
Winegar RA, 35:145–64
Witschi H, 37:29–52
Wolff MS, 36:573–96
Woosley RL, 36:233–52

Y

Yager JD, 36:203–32
Yamada H, 34:251–79
Yamane HK, 33:201–41
Yoshimura H, 34:251–79

Z

Zaki PA, 36:379–401
Zanger UM, 37:269–96
Zhang J, 35:213–33
Ziegler DM, 33:179–99
Zimmerman BG, 37:53–69

CHAPTER TITLES, VOLUMES 33–37

PREFATORY CHAPTERS		
The Quest for a Cure	GB Elion	33:1–23
Adventures in Autopharmacology: A Biographic View with Digressions into Other Matters	MJ Rand	33:25–44
From Peptides to Peptidases: A Chronicle of Drug Discovery	MA Ondetti	34:1–16
A Research Trail Over Half A Century	RF Furchgott	35:1–27
A Personal View of Pharmacology	J Black	36:1–33
A Career in Toxicology	RA Neal	36:35–46
A Rewarding Research Pathway	A Goldstein	37:1–28
ALLERGY AND DRUG SENSITIVITY		
Catecholamine Influences and Sympathetic Neural Modulation of Immune Responsiveness	KS Madden, VM Sanders, DL Felten	35:417–48
ANESTHETICS, ANALGESICS, AND ANTIINFLAMMATORY AGENTS		
Anti-inflammatory Peptide Agonists	ET Wei, HA Thomas	33:91–108
Targets for Antiinflammatory Drugs	BN Cronstein, G Weissmann	35:449–62
ANTIMICROBIAL, ANTIVIRAL, AND ANTIPARASITIC CHEMOTHERAPY		
Polyamines as Targets for Therapeutic Intervention	LJ Marton, AE Pegg	35:55–91
Molecular Mechanisms and Therapeutic Approaches to the Treatment of African Trypanosomiasis	CC Wang	35:93–127
Progress in Antisense Oligonucleotide Therapeutics	ST Crooke, CF Bennett	36:107–29
Structural Mechanisms of HIV Drug Resistance	JW Erickson, SK Burt	36:545–71
AUTONOMIC PHARMACOLOGY		
Pharmacologic and Therapeutic Applications of α_2-Adrenoceotor Subtypes	RR Ruffolo Jr, AJ Nichols, JM Stadel, JP Hieble	33:243–79
α_1-Adrenergic Receptor Subtypes	KP Minneman, TA Esbenshade	34:117–33
Structure and Function of the Beta$_3$-Adrenergic Receptor	AD Strosberg	37:421–50
BEHAVIORAL AND PSYCHOPHARMACOLOGY		
New Antidepressants	LE Hollister, JL Claghorn	33:165–77
Cardiovascular Toxicity of Anabolic Steroids	RW Rockhold	33:497–520
Relationships Between Lead-Induced Learning Impairments and Changes in Dopaminergic, Cholinergic, and Glutamatergic Neurotransmitter System Functions	DA Cory-Slechta	35:391–415
CNS Effects and Abuse Liability of Anabolic-Androgenic Steroids	SE Lukas	36:333–57
Pathophysiological Basis of Vulnerability to Drug Abuse: Role of an Interaction Between Stress, Glucocorticoids, and Dopaminergic Neurons	PV Piazza, M Le Moal	36:359–78

CANCER, CHEMOTHERAPY, AND IMMUNOPHARMACOLOGY		
HIV Drug Resistance	DD Richman	33:149–64
DNA Topoisomerases: Essential Enzymes and Lethal Targets	AY Chen, LF Liu	34:191–218
The ARYL Hydrocarbon Receptor Complex	Oliver Hankinson	35:307–40
Metallothioneins and Cell Death by Anticancer Drugs	JS Lazo, BR Pitt	35:635–53
Molecular Mechanisms of Toxicant-Induced Immunosuppression: Role of Second Messengers	MP Holsapple, JG Karras, JA Ledbetter, GL Schieven, SW Burchiel, DR Davila, AR Schatz, NE Kaminski	36:131–59
The Potential of Farnesyltransferase Inhibitors as Cancer Chemotherapeutics	JB Gibbs, A Oliff	37:143–66
CARDIOVASCULAR PHARMACOLOGY		
Pharmacology of the Endothelium in Ischemia-Reperfusion and Circulatory Shock	AM Lefer, DJ Lefer	33:71–90
Complement Activation and Inhibition in Myocardial Ischemia and Reperfusion Injury	JW Homeister, BR Lucchesi	34:17–40
Pharmacology of Cardiac and Vascular Remodeling	HAJ Struijker-Boudier, JFM Smits, JGR De Mey	35:509–39
Angiotensin Receptors and Their Therapeutic Implications	KK Griendling, B Lassègue, RW Alexander	36:281–306
Tissue Renin-Angiotensin Systems: A Site of Drug Action?	BG Zimmerman, EW Dunham	37:53–69
CLINICAL TOXICOLOGY AND DRUG INTERACTIONS		
Cardiac Actions of Antihistamines	RL Woosley	36:233–52
ELECTROLYTES AND MINERAL METABOLISM		
Molecular Strategies for Therapy of Cystic Fibrosis	JA Wagner, AC Chao, P Gardner	35:257–76
ENDOCRINE PHARMACOLOGY		
Effects of Opioids on the Hypothalamo-Pituitary-Adrenal Axis	RN Pechnick	33:353–82
Tamoxifen: Toxicities and Drug Resistance During the Treatment and Prevention of Breast Cancer	VC Jordan	35:195–211
Antiprogestins: Mechanism of Action and Contraceptive Potential	IM Spitz, HB Croxatto, A Robbins	36:47–81
Molecular Mechanisms of Estrogen Carcinogenesis	JD Yager, JG Liehr	36:203–32
Insulin Signal Transduction and the IRS Proteins	MG Myers Jr, MF White	36:615–58
Estrogens and Atherosclerosis	L Nathan, G Chaudhuri	37:477–515
ENVIRONMENTAL AND INDUSTRIAL PHARMACOLOGY AND TOXICOLOGY		
Respiratory Tract Uptake of Inhalants and Metabolism of Xenobiotics	AR Dahl, JL Lewis	33:383–407
Childhood Lead Poisoning and its Treatment	CR Angle	33:409–34
Carcinogenicity of TCDD: Experimental, Mechanistic, and Epidemiological Evidence	J Huff, G Lucier, A Tritscher	34:343–72
Risk Assessment of Environmental Chemicals	A Fan, R Howd, B Davis	35:341–68
Macrophages and Inflammatory Mediators in Tissue Injury	DL Laskin, KJ Pendino	35:655–77
Breast Cancer and Environmental Risk Factors: Epidemiological and Experimental Findings	MS Wolff, GW Collman, JC Barrett, J Huff	36:573–96

Enzymatic Methylation of Arsenic Species and Other New Approaches to Arsenic Toxicity	HV Aposhian	37:397–419
GASTROINTESTINAL PHARMACOLOGY		
The Pharmacology of the Gastric Acid Pump: The H^+, K^+ ATPase	G Sachs, JM Shin, C Briving, B Wallmark, S Hersey	35:277–305
MECHANISMS OF ACTION OF DRUGS AND CHEMICALS		
Calmodulin in Neurotransmitter and Hormone Action	ME Gnegy	33:45–70
Covalent Modifications of G-Proteins	HK Yamane, BK-K Fung	33:201–41
Gene Therapy, Concepts, Current Trials, and Future Directions	P Tolstoshev	33:573–96
Putative Mechanisms of Toxicity of 3-Methylindole: From Free Radical to Pneumotoxicosis	TM Bray, KS Emmerson	34:91–115
Mechanisms of Hepatocarcinogenicity of Peroxisome-Proliferating Drugs and Chemicals	BG Lake	35:483–507
P_2-Purinergic Receptors: Subtype-Associated Signaling Responses and Structure	TK Harden, JL Boyer, RA Nicholas	35:541–79
Pharmacology of Cannabinoid Receptors	AC Howlett	35:607–34
Diversity and Selectivity of Receptor-G Protein Interaction	T Gudermann, F Kalkbrenner, G Schultz	36:429–59
Complexity and Diversity of Mammalian Adenylyl Cyclases	RK Sunahara, CW Dessauer, AG Gilman	36:461–80
Regulation of Phosphoinositide Phospholipases by Hormones, Neurotransmitters, and Other Agonists Linked to G Proteins	JH Exton	36:481–509
Protein Targets of Xenobiotic Reactive Intermediates	NR Pumford, NC Halmes	37:91–117
G Protein Beta-Gamma Subunits	DE Clapham, EJ Neer	37:167–203
Pharmacology of Neurotrophic Factors	F Hefti	37:239–67
Structure-Function Aspects in the Nitric Oxide Synthases	DJ Stuehr	37:339–59
Molecular Determinants of Drug Binding and Action on L-Type Calcium Channels	GH Hockerman, BZ Peterson, BD Johnson, WA Catterall	37:361–96
The Heme Oxygenase System: A Regulator of Second-Messenger Gases	MD Maines	37:517–54
METABOLIC FATE OF DRUGS AND CHEMICALS		
Recent Studies on the Structure and Function of Multisubstrate Flavin-Containing Monooxygenases	DM Ziegler	33:179–99
Macromolecular Adducts: Biomarkers for Toxicity and Carcinogenesis	LW Chang, SMT Hsia, P-C Chan, L-L Hsieh	34:41–67
Regiochemistry of Cytochrome P450 Isozymes	K Oguri, H Yamada, H Yoshimura	34:251–79
Structural Basis of Selective Cytochrome P450 Inhibition	JR Halpert	35:29–53
Cytochromes P450 Expression Systems	FJ Gonzalez, KR Korzekwa	35:369–90
P-Glycoproteins and Multidrug Resistance	WT Bellamy	36:161–83
Structure-Based Drug Design: Computational Advances	TJ Marrone, JM Briggs, JA McCammon	37:71–90
Molecular Mechanisms of Genetic Polymorphisms of Drug Metabolism	UA Meyer, UM Zanger	37:269–96

MISCELLANEOUS		
The Role of the hsp90-Based Chaperone System in Signal Transduction by Nuclear Receptors and Receptor Signaling via MAP Kinase	WB Pratt	37:297–326
Medication Compliance as a Feature in Drug Development	H Kastrissios, TF Blaschke	37:451–75
NEUROMUSCULAR PHARMACOLOGY		
Reperfusion Injury After Liver Preservation for Transplantation	JJ Lemasters, RG Thurman	37:327–38
NEUROPHARMACOLOGY AND NEUROCHEMISTRY		
$GABA_B$ Receptor Pharmacology	NG Bowery	33:109–47
Neuropeptide Y-Related Peptides and Their Receptors—Are the Receptors Potential Therapeutic Drug Targets?	C Wahlestedt, DJ Reis	33:309–52
β-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease	B Cordell	34:69–89
Permeation Properties of Neurotransmitter Transporters	HA Lester, S Mager, MW Quick, JL Corey	34:219–49
The Cholinesterases: From Genes to Proteins	P Taylor, Z Radić	34:281–320
Inhibition of Constitutive and Inducible Nitric Oxide Synthase: Potential Selective Inhibition	JM Fukuto, G Chaudhuri	35:165–94
Nitric Oxide in the Nervous System	J Zhang, SH Snyder	35:213–33
Polyamine Regulation of *N*-Methyl-D-Aspartate Receptor Channels	DM Rock, RL Macdonald	35:463–82
Adenosine Receptor Subtypes: Characterization and Therapeutic Regulation	ME Olah, GL Stiles	35:581–606
Oxidative Stress in Neurodegenerative Diseases	NA Simonian, JT Coyle	36:83–106
Lipid vs Protein Theories of Alcohol Action in the Nervous System	RW Peoples, C Li, FF Weight	36:185–201
New Pharmacological Strategies for Pain Relief	A Dray, L Urban	36:253–80
Opioid Receptor Types and Subtypes: The δ Receptor as a Model	PA Zaki, EJ Bilsky, TW Vanderah, J Lai, CJ Evans, F Porreca	36:379–401
Imidazoline Receptors and Their Endogenous Ligands	S Regunathan, DJ Reis	36:511–44
Pharmacology of Nicotine: Addiction and Therapeutics	NL Benowitz	36:597–613
Exocytosis: Proteins and Perturbations	GJ Augustine, ME Burns, WM DeBello, DL Pettit, FE Schweizer	36:659–701
Pharmacology and Functions of Metabotropic Glutamate Receptors	PJ Conn, J-P Pin	37:205–37
PERINATAL AND DEVELOPMENTAL PHARMACOLOGY		
The Toxicology of Environmental Tobacco Smoke	H Witschi, JP Joad, KE Pinkerton	37:29–52
PHARMACOKINETICS, DRUG ABSORPTION, AND EXCRETION		
Absorption of Peptide and Peptidomimetic Drugs	GL Amidon, HJ Lee	34:321–41
PHARMACOLOGICALLY ACTIVE NATURAL SUBSTANCES		
Mechanisms of Aflatoxin Carcinogenesis	DL Eaton, EP Gallagher	34:135–72
Antagonists of Neuronal Calcium Channels: Structure, Function, and Therapeutic Implications	GP Miljanich, J Ramachandran	35:707–34
RENAL PHARMACOLOGY		
Renal Toxicity of Non-Steroidal Anti-Inflammatory Drugs	MD Murray, DC Brater	33:435–65

REPRODUCTION AND FERTILITY
Assessment of Follicle Destruction in Chemical-Induced Ovarian Toxicity — PB Hoyer, IG Sipes — 36:307–31

SMOOTH MUSCLE PHARMACOLOGY
Pharmacological Implications of the Flow-Dependence of Vascular Smooth Muscle Tone — JA Bevan, D Henrion — 34:173–90
Possible Role of Endothelin in Endothelial Regulation of Vascular Tone — T Masaki — 35:235–55
Kinins and Endothelial Control of Vascular Smooth Muscle — J-V Mombouli, PM Vanhoutte — 35:679–705
Cyclic Nucleotide Phosphodiesterases and Vascular Smooth Muscle — JB Polson, SJ Strada — 36:403–27

STRUCTURE-ACTIVITY RELATIONSHIPS AND MEDICINAL CHEMISTRY
Molecular Diversity of the Dopamine Receptors — O Civelli, JR Bunzow, DK Grandy — 33:281–307
The Pharmacology of Parkinson's Disease Therapy: An Update — IJ Kopin — 33:467–95
Prodrugs of Peptides and Proteins for Improved Formulation and Delivery — R Oliyai, VJ Stella — 33:521–44
Molecular and Ionic Mimicry of Toxic Metals — TW Clarkson — 33:545–71
The Pharmacology of ATP-Sensitive Potassium Channels — G Edwards, AH Weston — 33:597–637
Amphetamine: Effects on Catecholamine Systems and Behavior — LS Seiden, KE Sabol, GA Ricaurte — 33:639–77

TECHNIQUES
An Evaluation of the Role of Calcium in Cell Injury — AW Harman, MJ Maxwell — 35:129–44
Transgenic Animal Models for Detection of In Vivo Mutations — JC Mirsalis, JA Monforte, RA Winegar — 35:145–64
Transgenic Animals as New Approaches in Pharmacological Studies — L-N Wei — 37:119–41